On Thursday and Friday, the Food and Drug Administration convenes its independent advisers for the first stage in the process of deciding whether extra doses of the two vaccines should be dispensed and, if so, who should get them and when. The final go-ahead is not expected for at least another week.
AstraZeneca came out with a new study on a longer acting monoclonal antibody. The European vaccine producer found it prevented COVID-19 infections by as much as 77%, but there’s still more research to be done before it’s put to use.
J&J said it filed a request with the FDA to authorize boosters for people 18 and older who previously received the company’s one-shot vaccine. While the company said it submitted data on several different booster intervals, ranging from two to six months, it did not formally recommend one to regulators.
AstraZeneca, the Anglo-Swedish drugmaker that developed one of the first COVID-19 vaccines, has asked the U.S. Food and Drug Administration to authorize the emergency use of an antibody treatment to prevent the disease.